- Home
- MOLN vs YMAB Comparison
MOLN vs YMAB Comparison
Compare MOLN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- YMAB
- Stock Information
- Founded
- MOLN 2004
- YMAB 2015
- Country
- MOLN Switzerland
- YMAB United States
- Employees
- MOLN N/A
- YMAB N/A
- Industry
- MOLN
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- YMAB Health Care
- Exchange
- MOLN Nasdaq
- YMAB Nasdaq
- Market Cap
- MOLN 183.2M
- YMAB 218.4M
- IPO Year
- MOLN 2021
- YMAB 2018
- Fundamental
- Price
- MOLN $3.97
- YMAB $4.69
- Analyst Decision
- MOLN
- YMAB Buy
- Analyst Count
- MOLN 0
- YMAB 11
- Target Price
- MOLN N/A
- YMAB $18.73
- AVG Volume (30 Days)
- MOLN 4.2K
- YMAB 318.1K
- Earning Date
- MOLN 03-06-2025
- YMAB 05-06-2025
- Dividend Yield
- MOLN N/A
- YMAB N/A
- EPS Growth
- MOLN N/A
- YMAB N/A
- EPS
- MOLN N/A
- YMAB N/A
- Revenue
- MOLN $5,484,562.00
- YMAB $87,685,000.00
- Revenue This Year
- MOLN N/A
- YMAB N/A
- Revenue Next Year
- MOLN $528.57
- YMAB $21.10
- P/E Ratio
- MOLN N/A
- YMAB N/A
- Revenue Growth
- MOLN N/A
- YMAB 3.38
- 52 Week Low
- MOLN $3.32
- YMAB $3.86
- 52 Week High
- MOLN $12.70
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- MOLN 48.67
- YMAB 47.75
- Support Level
- MOLN $3.57
- YMAB $4.46
- Resistance Level
- MOLN $3.99
- YMAB $5.44
- Average True Range (ATR)
- MOLN 0.31
- YMAB 0.45
- MACD
- MOLN 0.04
- YMAB 0.07
- Stochastic Oscillator
- MOLN 46.46
- YMAB 52.53
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.